Dermatologicals
Refine Search
Biotechnology
US gene therapy company Krystal Biotech has finished building its manufacturing facility close to its Pittsburgh headquarters. 15 January 2019
Pharmaceutical
Peter Guenter has sought to keep up the pace of his turnaround of Spanish dermatology specialist Almirall. 4 January 2019
Biotechnology
Chinese drug developer Connect Biopharmaceuticals has completed a $55 million Series B financing led by new investor Advantech Capital with participation by current investors Qiming Venture Partners, Northern Light Venture Capital, and Cowin Venture. CEC Capital acted as the exclusive financial advisor for the financing. 3 January 2019
Generics
Teva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the USA. 31 December 2018
Pharmaceutical
DUSA Pharmaceuticals, a wholly-owned subsidiary of Sun Pharmaceutical Industries, has been granted preliminary injunctive relief by a federal district court prohibiting defendants Germany-based skin cancer specialist Biofrontera and its subsidiaries from using DUSA's confidential and proprietary trade secret information. 27 December 2018
Pharmaceutical
Indian drugmaker Glenmark Pharmaceuticals today announced its foray into the branded dermatology segment in the USA. 19 December 2018
Pharmaceutical
Ligand Pharmaceuticals yesterday announced the acquisition of economic rights to PTX-022 from fellow USA-based Palvella Therapeutics. 18 December 2018
Biotechnology
Eli Lilly saw its shares close down 3.19% at $108.36 yesterday, despite releasing positive clinical trial results with its interleukin (IL)-17 inhibitor compared to the world’s best selling prescription drug Humira (adalimumab). 18 December 2018
Biotechnology
Johnson & Johnson has announced positive data from the Phase III ECLIPSE study showing that Tremfya (guselkumab) was superior to Novartis’ Cosentyx (secukinumab) in moderate to severe plaque psoriasis. 13 December 2018
Biotechnology
The European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. 13 December 2018
Biotechnology
New research predicts that the atopic dermatitis market will grow from $6.4 billion in 2017 to $18.3 billion in 2027 across the seven major markets (7MM = USA, France, Germany, Italy, Spain, the UK, and Japan), expanding at a compound annual growth rate (CAGR) of 11.1%. 11 December 2018
Pharmaceutical
Among pharma M&A news last week, the big story was GlaxoSmithKline’s $5.1 billion acquisition of Tesaro and its cancer drug Zejula. On the licensing front, J&S’s Janssen unit struck a deal to develop argenx’ blood cancer drug cusatuzumab that could be worth $1.6 billion. Also, Revance Therapeutics’ China out-licensing deal for its Botox rival RT002 to Fosun was seen as a positive, as was the latest data from the SAKURA 3 trial. There was disappointment for Germany’ Bayer, as it halted a trial of its uterine fibroid candidate vilaprisan following toxicity concerns. 9 December 2018
Biotechnology
US biotech firm Revance Therapeutics saw its shares leap 19.5% to $24.91 by close of trading Tuesday, after it announced a licensing deal for its Botox rival (RT002 and some positive new clinical data for the investigational compound. 5 December 2018
Biotechnology
German biotech Evotec has entered into a new integrated drug discovery alliance with Denmark’s LEO Pharma, a global leader in medical dermatology, adding to a string of deals the German company has signed this year. 4 December 2018
Biotechnology
It’s been a busy year for Promore Pharma (Nasdaq: PROMO), a Swedish developer of therapeutic peptides, which has made good progress in its two clinical assets, making the investment case more attractive to investors, noted Klas Palin, analyst at Sweden’s Redeye Equity Research. 26 November 2018
Pharmaceutical
USA-based PellePharm is partnering with Denmark’s LEO Pharma to progress its rare skin cancer drug, in areas that have no approved treatments, such as Gorlin syndrome and high frequency basal cell carcinoma (BCC), two distinct and rare forms of skin cancer. 21 November 2018
Pharmaceutical
The turnaround at skin-focused pharma company Almirall shows no sign of abating. 12 November 2018
Biotechnology
Foamix Pharmaceuticals was up by 20% in pre-market trading on Wednesday after releasing results from Phase III studies of FMX103 1.5% minocycline foam. 7 November 2018
Biotechnology
Canadian drugmaker Zymeworks closed Tuesday’s trading more than 2% up after announcing that it had signed a deal with the privately-held Danish dermatology specialist, LEO Pharma. 24 October 2018
Pharmaceutical
Spain largest drugmaker Almirall has launched AlmirallShare, a new call with the aim of finding novel targets and concepts in the treatment of dermatological diseases. 11 October 2018
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze